Muna Bhanji
CIK: 0001846905
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (14 total)
- Oct 19, 2026VCYT
VERACYTE, INC.
Sale(S)Direct1.9K shares at avg. $43.70$81K - Sep 1, 2026VCYT
VERACYTE, INC.
Sale(S)Direct1.9K shares at avg. $42.97$80K - Jun 16, 2026ARDX
ARDELYX, INC.
Award(A)Direct26.5K shares- - Jun 11, 2026VCYT
VERACYTE, INC.
Award(A)Direct5.3K shares- - Jun 9, 2026NTLA
Intellia Therapeutics, Inc.
Award(A)Direct9.2K shares- - May 27, 2026CYTK
CYTOKINETICS INC
Award(A)Direct2.9K shares- - Jun 18, 2025ARDX
ARDELYX, INC.
Award(A)Direct41.6K shares- - Jun 18, 2025VCYT
VERACYTE, INC.
Award(A)Direct9.3K shares- - Jun 13, 2025VCYT
VERACYTE, INC.
Sale(S)Direct4.6K shares at avg. $26.67$122K - Jun 11, 2025NTLA
Intellia Therapeutics, Inc.
Award(A)Direct8K shares- - May 15, 2025CYTK
CYTOKINETICS INC
Sale(S)Direct1.5K shares at avg. $29.73$43K - May 14, 2025CYTK
CYTOKINETICS INC
Award(A)Direct7.3K shares- - Apr 29, 2025NTLA
Intellia Therapeutics, Inc.
Sale(S)Direct265 shares at avg. $8.50$2K - Jan 29, 2025NTLA
Intellia Therapeutics, Inc.
Sale(S)Direct265 shares at avg. $9.97$3K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 19, 2026 |  VCYT VERACYTE, INC. | Sale(S) | 1,864 | $43.70 | $81,457 | Direct |
| Sep 1, 2026 | VCYT VERACYTE, INC. | Sale(S) | 1,864 | $42.97 | $80,096 | Direct |
| Jun 16, 2026 |  ARDX ARDELYX, INC. | Award(A) | 26,455 | - | $0 | Direct |
| Jun 11, 2026 | VCYT VERACYTE, INC. | Award(A) | 5,272 | - | $0 | Direct |
| Jun 9, 2026 |  NTLA Intellia Therapeutics, Inc. | Award(A) | 9,200 | - | $0 | Direct |
| May 27, 2026 |  CYTK CYTOKINETICS INC | Award(A) | 2,851 | - | $0 | Direct |
| Jun 18, 2025 | ARDX ARDELYX, INC. | Award(A) | 41,551 | - | - | Direct |
| Jun 18, 2025 | VCYT VERACYTE, INC. | Award(A) | 9,321 | - | - | Direct |
| Jun 13, 2025 | VCYT VERACYTE, INC. | Sale(S) | 4,589 | $26.67 | $122,367 | Direct |
| Jun 11, 2025 | NTLA Intellia Therapeutics, Inc. | Award(A) | 8,000 | - | - | Direct |
| May 15, 2025 | CYTK CYTOKINETICS INC | Sale(S) | 1,454 | $29.73 | $43,227 | Direct |
| May 14, 2025 | CYTK CYTOKINETICS INC | Award(A) | 7,333 | - | - | Direct |
| Apr 29, 2025 | NTLA Intellia Therapeutics, Inc. | Sale(S) | 265 | $8.50 | $2,253 | Direct |
| Jan 29, 2025 | NTLA Intellia Therapeutics, Inc. | Sale(S) | 265 | $9.97 | $2,642 | Direct |
1-14 of 14 transactions
About Bhanji Muna
Bhanji Muna (SEC CIK 0001846905) files insider reports with the SEC as Director of VERACYTE, INC. (VCYT), Director of ARDELYX, INC. (ARDX) and Director of Intellia Therapeutics, Inc. (NTLA). Signal8 also holds filings tied to 1 other company.
Signal8 holds 14 ownership filings by Bhanji Muna, all Form 4s, filed between Jan 31, 2025 and Oct 20, 2026. Those filings report 14 transactions, from Jan 29, 2025 to Oct 19, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bhanji Muna's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Bhanji Muna
- Oct 19, 2026: Open-market sale of VCYT shares (Form 4, code S).
- Sep 1, 2026: Open-market sale of VCYT shares (Form 4, code S).
- Jun 16, 2026: Grant or award of ARDX shares (Form 4, code A).
- Jun 11, 2026: Grant or award of VCYT shares (Form 4, code A).
- Jun 9, 2026: Grant or award of NTLA shares (Form 4, code A).
Other insiders filing for VERACYTE, INC. (VCYT)
- Wygant Jonathan, VP, Chief Accounting Officer
- Holstein Jens, Director
- EASTHAM KARIN, Director
- Leite John, Global Chief Commercial Off
- Febbo Phillip G., Chief Scientific & Med Officer
- Chambers Rebecca, Chief Financial Officer